
Vaxcyte, Inc. – NASDAQ:PCVX
Vaxcyte stock price today
Vaxcyte stock price monthly change
Vaxcyte stock price quarterly change
Vaxcyte stock price yearly change
Vaxcyte key metrics
Market Cap | 10.81B |
Enterprise value | 1.43B |
P/E | -10.05 |
EV/Sales | N/A |
EV/EBITDA | -6.94 |
Price/Sales | N/A |
Price/Book | 2.35 |
PEG ratio | 0.12 |
EPS | -4.36 |
Revenue | N/A |
EBITDA | -406.5M |
Income | -436.82M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVaxcyte stock price history
Vaxcyte stock forecast
Vaxcyte financial statements
$137.44
Potential upside: 333.16%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 0 | -68.33M | |
---|---|---|---|
Sep 2023 | 0 | -92.66M | |
Dec 2023 | 14.44M | -180.80M | -1251.56% |
Mar 2024 | 0 | -95.02M |
Jun 2023 | 1502819000 | 69.44M | 4.62% |
---|---|---|---|
Sep 2023 | 1496057000 | 93.34M | 6.24% |
Dec 2023 | 1407917000 | 167.44M | 11.89% |
Mar 2024 | 2091305000 | 107.32M | 5.13% |
Jun 2023 | -62.74M | -333.56M | 546.96M |
---|---|---|---|
Sep 2023 | -57.54M | 22.28M | 48.55M |
Dec 2023 | -128.81M | -13.92M | 2.73M |
Mar 2024 | -159.12M | -451.07M | 818.19M |
Vaxcyte alternative data
Aug 2023 | 158 |
---|---|
Sep 2023 | 158 |
Oct 2023 | 158 |
Nov 2023 | 158 |
Dec 2023 | 158 |
Jan 2024 | 158 |
Feb 2024 | 158 |
Mar 2024 | 254 |
Apr 2024 | 254 |
May 2024 | 254 |
Jun 2024 | 254 |
Jul 2024 | 254 |
Vaxcyte other data
Period | Buy | Sel |
---|---|---|
Feb 2024 | 0 | 53000 |
Mar 2024 | 0 | 41961 |
Apr 2024 | 0 | 30283 |
May 2024 | 0 | 30283 |
Jun 2024 | 0 | 48483 |
Jul 2024 | 0 | 12283 |
Oct 2024 | 0 | 109098 |
Nov 2024 | 0 | 38250 |
Dec 2024 | 0 | 30366 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | PICKERING GRANT director, officer.. | Common Stock | 961 | $92.06 | $88,470 | ||
Sale | PICKERING GRANT director, officer.. | Common Stock | 1,029 | $92.03 | $94,701 | ||
Sale | PICKERING GRANT director, officer.. | Common Stock | 376 | $93.35 | $35,099 | ||
Option | EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & COR.. | Stock Option (right to buy) | 5,000 | $21.41 | $107,050 | ||
Option | EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & COR.. | Common Stock | 5,000 | $21.41 | $107,050 | ||
Sale | EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & COR.. | Common Stock | 1,435 | $90.16 | $129,384 | ||
Sale | EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & COR.. | Common Stock | 3,177 | $91.91 | $292,004 | ||
Sale | EYDELMAN MIKHAIL officer: SVP, GEN COUNSEL & COR.. | Common Stock | 388 | $92.9 | $36,046 | ||
Sale | PICKERING GRANT director, officer.. | Common Stock | 11,349 | $92.06 | $1,044,789 | ||
Sale | PICKERING GRANT director, officer.. | Common Stock | 1,409 | $93.06 | $131,123 |
Quarter | Transcript |
---|---|
Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q4 2022 27 Feb 2023 | Q4 2022 Earnings Call Transcript |
Q4 2021 28 Feb 2022 | Q4 2021 Earnings Call Transcript |
Q4 2020 29 Mar 2021 | Q4 2020 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Grant E. Pickering (1968) Co-Founder, Chief Executive Officer & Director | $750,920 |
Mr. James Wassil M.B.A., M.S. (1969) Chief Operating Officer | $651,060 |
Mr. Andrew L. Guggenhime M.B.A. (1968) Pres & Chief Financial Officer | $540,710 |
Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling
Sutro BioPharma: Good Stewardship Through Early Trials
Strong Financials And Pipeline Position Vaxcyte For Success
Vaxcyte: Positive Phase 2 Results Elevate Confidence In VAX-24's Potential
Vir Biotechnology: High Potential Returns With High Volatility Risks
Vaxcyte Has A Bright Future Ahead
Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
Week 26 MDA Breakout Stocks - July 2021: Short-Term Picks To Give You An Edge
-
What's the price of Vaxcyte stock today?
One share of Vaxcyte stock can currently be purchased for approximately $31.73.
-
When is Vaxcyte's next earnings date?
Unfortunately, Vaxcyte's (PCVX) next earnings date is currently unknown.
-
Does Vaxcyte pay dividends?
No, Vaxcyte does not pay dividends.
-
How much money does Vaxcyte make?
Vaxcyte has a market capitalization of 10.81B.
-
What is Vaxcyte's stock symbol?
Vaxcyte, Inc. is traded on the NASDAQ under the ticker symbol "PCVX".
-
What is Vaxcyte's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vaxcyte?
Shares of Vaxcyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vaxcyte's key executives?
Vaxcyte's management team includes the following people:
- Mr. Grant E. Pickering Co-Founder, Chief Executive Officer & Director(age: 57, pay: $750,920)
- Mr. James Wassil M.B.A., M.S. Chief Operating Officer(age: 56, pay: $651,060)
- Mr. Andrew L. Guggenhime M.B.A. Pres & Chief Financial Officer(age: 57, pay: $540,710)
-
Is Vaxcyte founder-led company?
Yes, Vaxcyte is a company led by its founder Mr. Grant E. Pickering.
-
How many employees does Vaxcyte have?
As Jul 2024, Vaxcyte employs 254 workers.
-
When Vaxcyte went public?
Vaxcyte, Inc. is publicly traded company for more then 5 years since IPO on 12 Jun 2020.
-
What is Vaxcyte's official website?
The official website for Vaxcyte is vaxcyte.com.
-
Where are Vaxcyte's headquarters?
Vaxcyte is headquartered at 825 Industrial Road, San Carlos, CA.
-
How can i contact Vaxcyte?
Vaxcyte's mailing address is 825 Industrial Road, San Carlos, CA and company can be reached via phone at +65 08370111.
-
What is Vaxcyte stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Vaxcyte in the last 12 months, the avarage price target is $137.44. The average price target represents a 333.16% change from the last price of $31.73.
Vaxcyte company profile:

Vaxcyte, Inc.
vaxcyte.comNASDAQ
254
Biotechnology
Healthcare
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
San Carlos, CA 94070
CIK: 0001649094
ISIN: US92243G1085
CUSIP: 92243G108